Country operational research priorities pending.
United States of America
The overall goal of this research proposal is to prioritize the five novel Bancroftian antigen candidates with respect to their ease-of-use and practicability within the frame of a future Wb123/WbAgx biplex test, based on their biophysical properties, stability data and behavior in our lateral flow assay setup. Along with the concurrent biochemical/clinical validation by the Nutman group. This will allow an informed choice as to which candidate antigen(s) should be used for the biplex assay development.
- An Ov16/OVOC3261 biplex IgG4 test, whereby we are confident that we can provide > 60% sensitivity and 99.8% specificity, as required by the TPP for Onchocerciasis Elimination Mapping.
- Demonstration that the Ov16/OVOC3261 biplex IgG4 test behaves at least as good with blood as with plasma/serum samples (notably a perceived weakness of the SD Ov16 RDT)
How does the performance of the new Ov16/Ov3261 test strip compare to that of the SD Ov16 RDT and the SD Ov16 ELISA?
Can serological markers for NTDs (particularly Loa loa and Lymphatic filariasis) be incorporated into geostatistical maps and used to guide program decisions around treatment and surveillance?
To test alternative rapid diagnostic test (RDT) formats for the Wb123 rapid test. In field trials, the current test format was less sensitive that FTS in post-MDA settings whereas alternative Wb123 test formats (ELISA, multiplex) were more sensitive. Our group uses new detection systems, based on nanoshells, to improve RDT performance.
To identify antigens that can be produced as recombinant proteins and to document elimination of schistosomiasis.
To identify antigens that differentiate between infections with Schistosoma mansoni and Schistosoma haematobium and that can be used in an ELISA, lateral flow assay or multiplex format.
Can a mobile reader be used to standardize the reading of rapid diagnostic tests (RDTs)?
Multi-lab comparison for STH PCR methods